{"result": "(\"entity\"<|>INGREDIENTES<|>EVENT<|>Ingredients are the components selected for clinical nutrition products, undergoing various tests to determine their suitability for formulation.)\n##\n(\"entity\"<|>ENSAYOS PRELIMINARES<|>EVENT<|>Preliminary tests are conducted on selected ingredients to assess their stability and technological functionality in the product.)\n##\n(\"entity\"<|>FORMULACIÓN<|>EVENT<|>Formulation is the process of creating a recipe that includes all necessary components to achieve the desired nutritional goals.)\n##\n(\"entity\"<|>RECETA<|>EVENT<|>A recipe is a detailed guide that outlines the specific ingredients and their quantities for creating clinical nutrition products.)\n##\n(\"entity\"<|>TABLA 3<|>EVENT<|>Table 3 presents various negative aspects that powdered ingredients may exhibit when mixed with water.)\n##\n(\"relationship\"<|>INGREDIENTES<|>NUTRICIÓN CLÍNICA<|>Ingredients are essential components in the development of clinical nutrition products<|>8)\n##\n(\"relationship\"<|>ENSAYOS PRELIMINARES<|>NUTRICIÓN CLÍNICA<|>Preliminary tests are a critical step in ensuring the quality of clinical nutrition products<|>8)\n##\n(\"relationship\"<|>FORMULACIÓN<|>NUTRICIÓN CLÍNICA<|>Formulation is the process that leads to the creation of clinical nutrition products<|>8)\n##\n(\"relationship\"<|>RECETA<|>NUTRICIÓN CLÍNICA<|>A recipe is a fundamental part of the formulation process for clinical nutrition products<|>8)\n##\n(\"relationship\"<|>TABLA 3<|>NUTRICIÓN CLÍNICA<|>Table 3 provides insights into the challenges faced during the formulation of clinical nutrition products<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: a la valoración de la Administración.\n\nPara cada uno de los ingredientes seleccionados, se realizarán una serie de ensayos preliminares acordes con la función que van a desempeñar en el producto. Se analizará, la estabilidad y la funcionalidad tecnológica de cada uno de ellos, para así poder decidir los ingredientes definitivos que entrarán a formar parte de los productos a desarrollar. Sobre los ingredientes se realizan análisis y ensayos focalizados en valorar la dispersión o solubilidad, granulometría, estabilidad térmica, salina y rango óptimo de pH o la capacidad espumante. Con el análisis de los resultados obtenidos tras estos ensayos se realiza una criba seleccionando aquellos que mejor se adapten a la tecnología y a las propiedades que queremos conferir al producto a desarrollar.\n\nCuando se han seleccionado todos los ingredientes que son susceptibles de ser usados en la nueva formulación, con ayuda de una aplicación para la generación de fórmulas, se calcula una que cumpla con todos los requisitos definidos (tabla 2), ejemplo de receta con cantidades en gramos por cada 100 ml.\n\nTabla 2. Ejemplo de una receta de una fórmula para nutrición enteral.\n\n| Ingrediente          | Cantidad (g) |\n|----------------------|--------------|\n| Agua                 | 79,24        |\n| Maltodextrina M      | 10,00        |\n| Proteínas de la leche P | 5,00      |\n| Aceite vegetal V1    | 3,00         |\n| Aceite vegetal V2    | 1,00         |\n| Emulgente E          | 0,03         |\n| Mezcla de minerales  | 0,50         |\n| Mezcla de vitaminas  | 0,20         |\n| Aroma A              | 1,00         |\n| Edulcorante E1       | 0,02         |\n| Estabilizante Ea     | 0,01         |\n---\n## BLOQUE: NUTRICIÓN Y ASPECTOS LEGALES\n\n### 4. Metodología para el desarrollo de productos de nutrición clínica\n\nEl siguiente paso tras realizar el diseño teórico del producto es esbozar una receta que contenga todos los componentes necesarios para alcanzar los objetivos requeridos, comenzando así los ensayos de formulación y proceso a escala laboratorio con las materias primas, ingredientes y tratamientos de elaboración y conservación para valorar solubilidad, viscosidad, sabor, etc. Esta tarea implica una compleja interacción de factores técnicos y comerciales. Es necesario valorar cuestiones tales como la interacción de los ingredientes con la matriz alimentaria o las tecnologías a emplear para conseguir un producto de elevadas cualidades nutricionales pero a la vez sensorialmente apetecible por los consumidores durante un amplio período de vida útil. Conjugando ambos factores conseguiremos obtener diferentes prototipos de producto a escala laboratorio.\n\n#### 4.1. Mezcla: adición de ingredientes, desaireación y homogeneización\n\nLos productos de nutrición clínica son, en su mayoría, una combinación de agua con ingredientes líquidos (formando una emulsión) y en polvo (formando una suspensión), por lo tanto el establecimiento del proceso de recombinación de los mismos es el primer paso del desarrollo. Una mezcla realizada de manera eficiente mejora la uniformidad del producto, su posterior procesado y, por lo tanto, su calidad.\n\nLos defectos que se pueden encontrar más habitualmente en una mezcla son los que se reflejan en la figura 1.\n\nLa teoría de la sedimentación viene determinada por la ley de Stokes:\n\n$$V = \\frac{d^2(p_1 - p)}{18 n} g$$\n\nSegún esta ecuación, la velocidad de sedimentación de las partículas depende del tamaño de la misma (d), de la densidad de la partícula (p₁) y del medio (p), de la viscosidad (n), siendo g la constante de gravedad. Por lo tanto, teniendo en cuenta estos parámetros, la estabilidad de la suspensión se fomentará reduciendo el tamaño de partícula de los ingredientes y aumentando la viscosidad del medio²⁰.\n\n#### 4.1.1. Suspensión\n\nLa meta en la mezcla es lograr la estabilidad, ya que las suspensiones son inestables, dando lugar a sedimentación, o si debido a las fuerzas electrostáticas entre las partículas, se agrupan generando floculación.\n\nCuando el ingrediente en polvo entra en contacto con un líquido, este penetra por capilaridad a través de los poros del grano aumentando el área de contacto. Pero esta capacidad de hidratación de los ingredientes depende a su vez de su naturaleza; en la tabla 3 se pueden ver algunos aspectos negativos que pueden presentar los ingredientes en polvo al entrar en contacto con el agua.\n\nLa adición de estabilizantes, como las gomas, repercute en un aumento de la viscosidad de la mezcla dismin\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>NUTRICIÓN CLÍNICA<|>EVENT<|>Nutritional clinical products are developed through a complex interaction of technical and commercial factors, focusing on achieving high nutritional quality and sensory appeal for consumers.)\n##\n(\"entity\"<|>AGUA<|>INGREDIENT<|>Water is a primary ingredient in clinical nutrition products, forming the base of emulsions and suspensions.)\n##\n(\"entity\"<|>MALTODextrina M<|>INGREDIENT<|>Maltodextrin M is a carbohydrate used in clinical nutrition formulations to provide energy.)\n##\n(\"entity\"<|>PROTEÍNAS DE LA LECHE P<|>INGREDIENT<|>Milk proteins P are included in clinical nutrition products for their nutritional value and role in muscle maintenance.)\n##\n(\"entity\"<|>ACEITE VEGETAL V1<|>INGREDIENT<|>Vegetable oil V1 is used in formulations to provide essential fatty acids and improve palatability.)\n##\n(\"entity\"<|>ACEITE VEGETAL V2<|>INGREDIENT<|>Vegetable oil V2 is another source of essential fatty acids in clinical nutrition products.)\n##\n(\"entity\"<|>EMULGENTE E<|>INGREDIENT<|>Emulsifier E helps stabilize mixtures of oil and water in clinical nutrition formulations.)\n##\n(\"entity\"<|>MEZCLA DE MINERALES<|>INGREDIENT<|>Mineral mix is included to ensure that clinical nutrition products meet dietary mineral requirements.)\n##\n(\"entity\"<|>MEZCLA DE VITAMINAS<|>INGREDIENT<|>Vitamin mix is added to provide essential vitamins necessary for health in clinical nutrition products.)\n##\n(\"entity\"<|>AROMA A<|>INGREDIENT<|>Flavoring A is used to enhance the taste of clinical nutrition products.)\n##\n(\"entity\"<|>EDULCORANTE E1<|>INGREDIENT<|>Sweetener E1 is included to improve the sweetness of clinical nutrition formulations without adding calories.)\n##\n(\"entity\"<|>ESTABILIZANTE EA<|>INGREDIENT<|>Stabilizer EA is used to maintain the consistency and texture of clinical nutrition products.)\n##\n(\"entity\"<|>TABLA 2<|>EVENT<|>Table 2 provides an example recipe for enteral nutrition, detailing ingredient quantities for formulation.)\n##\n(\"relationship\"<|>NUTRICIÓN CLÍNICA<|>TABLA 2<|>The methodology for developing clinical nutrition products is exemplified in Table 2, which outlines a specific recipe<|>7)\n##\n(\"relationship\"<|>AGUA<|>NUTRICIÓN CLÍNICA<|>Water is a fundamental ingredient in the formulation of clinical nutrition products<|>8)\n##\n(\"relationship\"<|>MALTODextrina M<|>NUTRICIÓN CLÍNICA<|>Maltodextrin M is a key ingredient used in clinical nutrition formulations<|>8)\n##\n(\"relationship\"<|>PROTEÍNAS DE LA LECHE P<|>NUTRICIÓN CLÍNICA<|>Milk proteins P are essential for the nutritional quality of clinical nutrition products<|>8)\n##\n(\"relationship\"<|>ACEITE VEGETAL V1<|>NUTRICIÓN CLÍNICA<|>Vegetable oil V1 contributes to the nutritional profile of clinical nutrition products<|>8)\n##\n(\"relationship\"<|>ACEITE VEGETAL V2<|>NUTRICIÓN CLÍNICA<|>Vegetable oil V2 is included in clinical nutrition formulations for its nutritional benefits<|>8)\n##\n(\"relationship\"<|>EMULGENTE E<|>NUTRICIÓN CLÍNICA<|>Emulsifier E is necessary for the stability of clinical nutrition products<|>8)\n##\n(\"relationship\"<|>MEZCLA DE MINERALES<|>NUTRICIÓN CLÍNICA<|>Mineral mix is vital for meeting dietary requirements in clinical nutrition products<|>8)\n##\n(\"relationship\"<|>MEZCLA DE VITAMINAS<|>NUTRICIÓN CLÍNICA<|>Vitamin mix is crucial for the health benefits of clinical nutrition products<|>8)\n##\n(\"relationship\"<|>AROMA A<|>NUTRICIÓN CLÍNICA<|>Flavoring A enhances the sensory appeal of clinical nutrition products<|>8)\n##\n(\"relationship\"<|>EDULCORANTE E1<|>NUTRICIÓN CLÍNICA<|>Sweetener E1 improves the taste of clinical nutrition formulations<|>8)\n##\n(\"relationship\"<|>ESTABILIZANTE EA<|>NUTRICIÓN CLÍNICA<|>Stabilizer EA is important for maintaining the quality of clinical nutrition products<|>8)\n<|COMPLETE|>"}]}